GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioRestorative Therapies Inc (NAS:BRTX) » Definitions » ROC (Joel Greenblatt) %

BioRestorative Therapies (BioRestorative Therapies) ROC (Joel Greenblatt) % : -2,659.24% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is BioRestorative Therapies ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. BioRestorative Therapies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -2,659.24%.

The historical rank and industry rank for BioRestorative Therapies's ROC (Joel Greenblatt) % or its related term are showing as below:

BRTX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4587.27   Med: -2141.91   Max: -1287.6
Current: -2857.3

During the past 13 years, BioRestorative Therapies's highest ROC (Joel Greenblatt) % was -1287.60%. The lowest was -4587.27%. And the median was -2141.91%.

BRTX's ROC (Joel Greenblatt) % is ranked worse than
80.31% of 1468 companies
in the Biotechnology industry
Industry Median: -338.875 vs BRTX: -2857.30

BioRestorative Therapies's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -1.30% per year.


BioRestorative Therapies ROC (Joel Greenblatt) % Historical Data

The historical data trend for BioRestorative Therapies's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioRestorative Therapies ROC (Joel Greenblatt) % Chart

BioRestorative Therapies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,283.07 -1,669.50 -4,587.27 -3,062.34 -2,779.98

BioRestorative Therapies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3,389.10 -3,911.34 -2,268.97 -2,520.13 -2,659.24

Competitive Comparison of BioRestorative Therapies's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, BioRestorative Therapies's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioRestorative Therapies's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where BioRestorative Therapies's ROC (Joel Greenblatt) % falls into.



BioRestorative Therapies ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.039 + 0 + 0.326) - (0.776 + 0 + 0.001)
=-0.412

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.019 + 0 + 0.306) - (0.901 + 0 + 0)
=-0.576

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of BioRestorative Therapies for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-12.884/( ( (0.461 + max(-0.412, 0)) + (0.508 + max(-0.576, 0)) )/ 2 )
=-12.884/( ( 0.461 + 0.508 )/ 2 )
=-12.884/0.4845
=-2,659.24 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioRestorative Therapies  (NAS:BRTX) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


BioRestorative Therapies ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of BioRestorative Therapies's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioRestorative Therapies (BioRestorative Therapies) Business Description

Traded in Other Exchanges
Address
40 Marcus Drive, Suite One, Melville, NY, USA, 11747
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Executives
Dale Broadrick 10 percent owner 3003 BRICK CHURCH PIKE, NASHVILLE TN 37207
Lance Alstodt director, 10 percent owner, officer: President, CEO, COB BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE NY 11747
Francisco Silva director, 10 percent owner, officer: VP of Research and Development STEM CELL ASSURANCE, INC., 555 HERITAGE DRIVE, JUPITER FL 33458
Robert Eugene Kristal officer: Chief Financial Officer 4719 COLE AVENUE, DALLAS TX 75205
Patrick F. Williams director C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
David A Rosa director 10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Nickolay V. Kukekov director 4524 WESTWAY AVE, DALLAS TX 75205
Mark Weinreb director, 10 percent owner, officer: CEO and Chairman of the Board STEM CELL ASSURANCE, INC., 555 HERITAGE DRIVE, JUPITER FL 33458
Paul Jude Tonna director 69 CHICHESTER ROAD, HUNTINGTON NY 11743
A. Jeffrey Radov director 8 WALWORTH AVENUE, SCARSDALE NY 10583
Robert Paccasassi officer: VP, Quality and Compliance C/O BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE NY 11747
Robert B Catell director 62 OSBORNE ROAD, GARDEN CITY NY 11530
Adam D. Bergstein officer: SVP, Planning and Business Dev 167 HAZEL AVENUE, GLENCOE IL 60022
John M Desmarais director 230 PARK AVENUE, NEW YORK NY 10169
Westbury Trust 10 percent owner VICTORIA HALL, 11 VICTORIA STREET, P.O. BOX HM 1065, HAMILTON D0 00000

BioRestorative Therapies (BioRestorative Therapies) Headlines

From GuruFocus